Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 7/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061123 | 0.88 | SLC22A12 (0.51) | SLC22A12ARCNR2 | |
| SCHEMBL3059987 | 0.85 | SLC22A12 (0.50) | SLC22A12ARCNR2 | |
| SCHEMBL3289311 | 0.82 | AR (0.52) | SLC22A12AR | |
| SCHEMBL18974782 | 0.82 | SLC22A12 (0.53) | SLC22A12ARCNR2 | |
| SCHEMBL3057215 | 0.81 | AR (0.55) | SLC22A12AR | |
| SCHEMBL20702470 | 0.81 | SLC22A12 (0.49) | SLC22A12ARCNR2 | |
| SCHEMBL14685064 | 0.79 | SLC22A12 (0.50) | SLC22A12ARCNR2 | |
| SCHEMBL3288072 | 0.79 | SLC22A12 (0.50) | SLC22A12ARCNR2 | |
| SCHEMBL3289361 | 0.78 | AR (0.52) | SLC22A12AR | |
| SCHEMBL3414215 | 0.78 | AR (0.51) | SLC22A12AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089974-B1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA SAS (FR) | 2019-02-20 | — | — | EP | disclosed |
| CN-105849101-B | New imidazolidine -2,4- derovatives | 益普生制药股份有限公司 | 2019-02-19 | — | — | CN | disclosed |
| US-9975880-B2 | Imidazolidine-2,4-dione dervatives | IPSEN PHARMA S.A.S. (FR) | 2018-05-22 | — | — | US | disclosed |
| EP-3089974-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA S.A.S. (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-20160318908-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA S.A.S. (FR) | 2016-11-03 | — | — | US | disclosed |
| WO-2015100617-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | BEAUFOUR-IPSEN (TIANJIN) PHARMACEUTICAL CO., LTD. (CN) | 2015-07-09 | — | — | WO | disclosed |
| EP-1122242-B1 | CYANOPHENYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-20040010037-A1 | Cyanophenyl derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2004-01-15 | — | — | US | disclosed |
| US-6673799-B1 | INHIBITS BINDING TO ANDROGEN RECEPTOR; ANTIANDROGEN | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1122242-A1 | CYANOPHENYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010037-A1 | Cyanophenyl derivative | BPHL, AR, KLK3 | SLC22A12 2296/4885AR 2/4885CNR2 815/4885 |
| US-20160318908-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | MKI67, CCNI, CDKN1A | SLC22A12 2904/4885AR 3424/4885CNR2 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.